Structure Therapeutics (GPCR) Capital Expenditures (2022 - 2026)

Structure Therapeutics' Capital Expenditures history runs 5 years deep, the most recent figure standing at $1.2 million for Q1 2026.

• In Q1 2026, Capital Expenditures rose 19.39% year-over-year to $1.2 million; the TTM figure through Mar 2026 stood at $3.8 million (down 37.08% YoY), while the FY2025 annual figure was $3.6 million, down 28.59% from the prior year.
• Capital Expenditures for Q1 2026 stood at $1.2 million, down from $2.1 million in the prior quarter.
• The five-year high for Capital Expenditures was $3.8 million in Q4 2024, with the low at -$444000.0 in Q2 2025.
• The 5-year median for Capital Expenditures is $72000.0 (2022), against an average of $586176.5.
• The sharpest annual moves came in 2023 and 2025: Capital Expenditures slumped 1000.0% in 2023, then soared 49400.0% in 2025.
• Structure Therapeutics' Capital Expenditures stood at -$24000.0 in 2022, then plunged by 1000.0% to -$264000.0 in 2023, then jumped by 1534.47% to $3.8 million in 2024, then slumped by 43.99% to $2.1 million in 2025, then tumbled by 44.27% to $1.2 million in 2026.
• Business Quant data shows GPCR's Capital Expenditures at $1.2 million in Q1 2026, $2.1 million in Q4 2025, and $947000.0 in Q3 2025.